Odawara, Japan

Maki Shiobara


Average Co-Inventor Count = 13.0

ph-index = 1

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 2002-2007

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Maki Shiobara: Innovator in Antiallergic Agents

Introduction

Maki Shiobara is a prominent inventor based in Odawara, Japan. She has made significant contributions to the field of pharmaceuticals, particularly in the development of antiallergic agents. With a total of 3 patents to her name, her work has garnered attention for its innovative approaches to allergy treatment.

Latest Patents

Maki Shiobara's latest patents include the development of tricyclic triazolobenzazepine derivatives, which are designed to serve as effective antiallergic agents. These compounds are presented in the form of prodrugs, showcasing excellent bioavailability. The compounds are represented by specific formulas, with various pharmacologically acceptable salts and solvates. Additionally, she has outlined a detailed process for producing these compounds, which involves multiple chemical reactions to achieve the desired antiallergic properties.

Career Highlights

Throughout her career, Maki Shiobara has worked with notable companies such as Meiji Seika Kaisha, Ltd. Her experience in these organizations has allowed her to refine her expertise in pharmaceutical innovation and contribute to the advancement of allergy treatments.

Collaborations

Maki has collaborated with esteemed colleagues, including Yasuo Ohtsuka and Toshio Nishizuka. These partnerships have played a crucial role in her research and development efforts, leading to significant advancements in her field.

Conclusion

Maki Shiobara's contributions to the development of antiallergic agents highlight her innovative spirit and dedication to improving healthcare. Her work continues to influence the pharmaceutical industry and offers promising solutions for allergy sufferers.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…